BenevolentAI, an AI-driven biopharma drug discovery company, announced that it has appointed Joerg Moeller as chief executive officer and executive board member, effective immediately.
Moeller’s most recent role was as EVP, head of Global Research and Development at LEO Pharma, where he reorganized the R&D organization for growth and innovation. His career includes over 20 years at Bayer, where he held various executive roles, culminating in EVP, head of Pharmaceuticals R&D.
Last May, BenevolentAI unveiled organizational restructuring plans, which included a headcount reduction and reprioritization of its pipeline. The company narrowed its focus to two early-stage assets: a potentially best-in-class PDE10 inhibitor for the treatment of ulcerative colitis and a CHK1 inhibitor designed for treating a type of brain tumor.
In September, the company inked a $594 million dead with Merck, handing over its end-to-end AI platform to help the drugmaker identify and develop innovative compounds from Hit Identification (Hit ID) to the pre-clinical stage.
